Rhythm Biosciences (ASX:RHY) completed the acquisition of select Australian and US assets related to the Genetype business from Genetic Technologies (ASX:GTG) for AU$625,000, according to a Tuesday filing with the Australian bourse.
The company paid the administrators of Genetic Technologies and select trade creditors the necessary cash amounts and assumed statutory employee entitlements for transferring employees in Australia, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.